SELLAS Life Sciences Group, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 12, 2026, reporting consolidated financial results and balance sheet data for the third quarter.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $134,711 thousand as of September 30, 2026, up from $71,793 thousand at December 31, 2025.
  • Total assets: Total assets were $141,091 thousand at September 30, 2026, compared with $78,345 thousand at December 31, 2025.
  • Shares outstanding: As of November 11, 2026, the company had 203,859,151 shares of common stock outstanding.
  • Share count increase: Shares issued and outstanding grew from 153,103,459 at December 31, 2025 to 203,527,833 at September 30, 2026.
  • Additional paid-in capital: Additional paid-in capital rose to $434,876 thousand from $345,844 thousand at December 31, 2025.
  • Total liabilities: Total liabilities were $9,286 thousand at September 30, 2026, compared with $7,474 thousand at December 31, 2025.

SELLAS Life Sciences Balance Sheet and Capital Position for the Quarter Ended September 30, 2026

According to the filing, SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) reported total assets of $141,091 thousand as of September 30, 2026, a significant increase from $78,345 thousand at December 31, 2025. The primary driver of that increase, as disclosed, was a rise in cash and cash equivalents from $71,793 thousand to $134,711 thousand over the same period. Restricted cash and cash equivalents remained at $100 thousand at both dates.

The company disclosed that additional paid-in capital increased to $434,876 thousand at September 30, 2026 from $345,844 thousand at December 31, 2025, alongside an increase in shares issued and outstanding from 153,103,459 to 203,527,833. The par value of common stock is $0.0001 per share, with 350,000,000 shares authorized, according to the filing. The company is classified as a non-accelerated filer and a smaller reporting company, as indicated on the cover page.

On the liabilities side, the filing reported total liabilities of $9,286 thousand at September 30, 2026, compared with $7,474 thousand at December 31, 2025. Accrued expenses and other current liabilities rose to $6,598 thousand from $3,525 thousand, while accounts payable declined to $2,089 thousand from $2,948 thousand. The filing notes that the company's forward-looking statements are subject to risks and uncertainties and that actual results could differ materially, as described in its cautionary language.

What Was Disclosed

SELLAS Life Sciences filed its quarterly report covering the period ended September 30, 2026, disclosing balance sheet data showing higher cash, total assets, additional paid-in capital, and share count compared with year-end 2025, alongside modestly higher total liabilities.